Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma

Leukemia & Lymphoma
Y CohenA Goldfarb

Abstract

Cold agglutinin mediated immune hemolytic anemia secondary to lymphoproliferative disease (LPD), is primarily treated with measures directed to eliminate the malignant clone and as such, chemotherapy is usually given. The recent availability of monoclonal antibodies, has made it feasible to obtain both a clinical and molecular remission, as well as a remission on the functional level, such as elimination of secondary autoimmune phenomena. Recently we have administered a course of monotherapy with rituximab (4 weekly injections, x 375 mg/m2) to a patient with refractory and transfusion dependent cold agglutinin mediated hemolytic anemia secondary to indolent B-cell lymphoma. She achieved complete remission with a significant improvement in hemolysis and also became transfusion independent with a current follow-up of over one year. In individual cases, Rituximab has the potential of achieving not only a complete clinical remission (CR) but also a molecular CR, as well as a "functional" CR, by eliminating the clinical manifestations of autoimmunity; in this case, cold agglutinin mediated hemolytic anemia, secondary to NHL. Good results in autoimmunity secondary to lymphoma raises the possibility of future potential benefit of this...Continue Reading

Citations

Sep 5, 2002·Arthritis and Rheumatism·Dhavalkumar D Patel
Dec 23, 2003·International Journal of Hematology·Anat Galor, Timothy O'Brien
Apr 20, 2004·Advanced Drug Delivery Reviews·Yingjuan LuPhilip S Low
Oct 11, 2003·Transplant Immunology·Carsten SchröderRichard N Pierson
Mar 9, 2004·Autoimmunity Reviews·Yossi Cohen, Arnon Nagler
Jan 30, 2004·Annual Review of Medicine·William RastetterChristine A White
Aug 16, 2011·Annales pharmaceutiques françaises·Y SekkachD Ghafir
May 7, 2011·Advances in Hematology·Claudio Fozza, Maurizio Longinotti
Feb 15, 2012·Blood Reviews·Sigbjørn Berentsen, Geir E Tjønnfjord
Oct 26, 2012·The Journal of Investigative Dermatology·Roghieh DjafarzadehPeter J Nelson
Jul 13, 2004·Clinical Lymphoma·Karl T Hagler, James W Lynch
Feb 14, 2004·European Journal of Haematology·Tadeusz Robak
Mar 10, 2011·British Journal of Haematology·Sigbjørn Berentsen
Jun 15, 2004·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Luigi Virgolini, Vanda Marzocchi
Sep 20, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Robert Eisenberg, R John Looney
Jun 13, 2013·Blood·Paul L SwiecickiMorie A Gertz
Oct 21, 2004·American Journal of Hematology·Elpis MantadakisMaria Kalmanti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.